JPRN-UMIN000007961
Recruiting
Phase 1
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancer - Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with refractory esophageal cancer
ConditionsRefractory esophageal cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Refractory esophageal cancer
- Sponsor
- Kyoto Prefectural University of Medicine
- Enrollment
- 18
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Past history of severe hypersensitivity 2\. Positive for HIV antibody 3\. Experience of autoimmune disease requiring treatment during 6 months preceding the day of consent 4\. Use of steroids (more than 20 mg equivalent of prednisolone/day) or immunosuppressive drugs 5\. Patients with following severe complications \# severe heart disease or uncontrolled angina \# Uncontrolled diabetes mellitus \# Intestinal paresis or ileus \# Active infections requiring antibiotics \# Other severe complications 6\. Pregnant or lactating women 7\. Inappropriate for study entry judged by an attending physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate CancerJPRN-UMIN000005246Mie University Graduate School of Medicine12
Completed
Phase 1
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
Completed
Not Applicable
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45
Not yet recruiting
Not Applicable
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
Completed
Not Applicable
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9